1 Regulatory Legislation and Guidelines for Recombinant Drugs, Pharmaceuticals and Biologicals K.K. Tripathi* Department of Biotechnology (Ministry of.
IMS Health 2011 Strengths and Limitations of Market Intelligence Data for Pharmaceutical Policy Analysis in LMIC ICIUM 2011 - Third International Conference.
Pharmaceutical Policy – Focus on Pricing, Reimbursement and Industrial Policy
Samia Saad 1 , Birgit Kerstens 2 , Wilbert Bannenberg 1,2
Samia Saad 1, Birgit Kerstens 2, Wilbert Bannenberg 1,2 1 Medicines Transparency Alliance (MeTA) Pilot, United Kingdom; 2 Health Research for Action (HERA),
Gender and Access to Medicines in 15 Low- and Middle-Income Countries: Does Physician Prescribing for Men and Women Differ? Stephens, Peter (1); Ross-Degnan,
Regulatory Legislation and Guidelines for Recombinant Drugs, Pharmaceuticals and Biologicals
Pharmaceutical Policy in Canada : Reflections on a Shifting Landscape
ABSTRACT 1013
Policy, Advocacy, and Regulation, One Health Course
